Drug
long-acting injectable risperidone
long-acting injectable risperidone is a pharmaceutical drug with 3 clinical trials. Historical success rate of 66.7%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_4
2
67%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (33.3%)
Phase 42 (66.7%)
Trials by Status
completed267%
terminated133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_4
High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone
NCT00539071
terminatedphase_4
Optimizing Response in Psychosis Study
NCT00314327
completedphase_2
A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence
NCT00284206
Clinical Trials (3)
Showing 3 of 3 trials
NCT00539071Phase 4
High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone
NCT00314327Phase 4
Optimizing Response in Psychosis Study
NCT00284206Phase 2
A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3